Abstract | PURPOSE: PATIENTS AND METHODS: From January 1995 to July 2003, 40 patients with grade III gliomas were treated with fractionated stereotactic reirradiation at the time point of recurrence. Median size of planning target volume for reirradiation was 56.2 ml (range 25.1-296.2 ml). A median target total dose of 36 Gy (range 20-57.6 Gy) was applied using a median fractionation of 5 x 2 Gy/week with a 6-MeV linear accelerator. RESULTS:
Radiotherapy was well tolerated by all patients. No toxicities > CTC grade 2 developed. Median overall survival calculated from the time point of primary diagnosis was 48 months (range 7-180 months). The 5- and 10-year overall survival rates were 49.5% and 24.7%, respectively. From the time point of reirradiation, median survival was 16 months (range 1-98 months). Median progression-free survival from the time point of reirradiation was 8 months (range 1-72 months). No prognosticators for survival or progression-free survival after reirradiation could be identified. CONCLUSION:
|
Authors | Stephanie E Combs, Sybille Gutwein, Christoph Thilmann, Jürgen Debus, Daniela Schulz-Ertner |
Journal | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
(Strahlenther Onkol)
Vol. 181
Issue 12
Pg. 768-73
(Dec 2005)
ISSN: 0179-7158 [Print] Germany |
PMID | 16362786
(Publication Type: Clinical Trial, Journal Article)
|
Topics |
- Adult
- Aged
- Astrocytoma
(classification, mortality, pathology, surgery)
- Brain Neoplasms
(classification, mortality, pathology, surgery)
- Dose Fractionation, Radiation
- Female
- Germany
(epidemiology)
- Humans
- Incidence
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(classification, mortality, pathology, surgery)
- Prognosis
- Radiosurgery
(statistics & numerical data)
- Risk Assessment
(methods)
- Risk Factors
- Severity of Illness Index
- Survival Analysis
- Survival Rate
- Treatment Outcome
- World Health Organization
|